WASHINGTON, March 20, 2009 (GLOBE NEWSWIRE) -- Finkelstein Thompson LLP is investigating claims that the members of the Board of Directors of Emageon, Inc. (Nasdaq:EMAG) may have breached their fiduciary duties in connection with AMICAS, Inc's proposed cash tender offer for all outstanding shares of Emageon at a purchase price of $1.82 per share. Specifically, the investigation is focused on claims that the Board wrongfully failed to maximize value for the Company's stockholders when negotiating and entering into the agreement with AMICAS.
If you are interested in discussing your rights as an Emageon shareholder, or have information relating to this investigation, please contact Finkelstein Thompson's Washington, DC offices at (877) 337-1050 or by email at contact@finkelsteinthompson.com.
Finkelstein Thompson LLP has spent over three decades delivering outstanding representation to institutional and individual clients in connection with securities and other finance-related litigation, and has been appointed as lead or co-lead counsel in dozens of shareholder class actions. Indeed, the firm has served in leadership roles in cases that have recovered over $1 billion for investors and consumers. To learn more about Finkelstein Thompson LLP, please visit our web site at www.finkelsteinthompson.com.